{"id":22715,"date":"2023-06-19T14:34:46","date_gmt":"2023-06-19T12:34:46","guid":{"rendered":"https:\/\/kymos.com\/news\/productes-medicinals-de-terapia-avancada-primera-plataforma-per-a-virus-adenoassociats-en-terapia-genica\/"},"modified":"2023-06-19T14:34:46","modified_gmt":"2023-06-19T12:34:46","slug":"productes-medicinals-de-terapia-avancada-primera-plataforma-per-a-virus-adenoassociats-en-terapia-genica","status":"publish","type":"post","link":"https:\/\/kymos.com\/ca\/news\/productes-medicinals-de-terapia-avancada-primera-plataforma-per-a-virus-adenoassociats-en-terapia-genica\/","title":{"rendered":"Productes medicinals de ter\u00e0pia avan\u00e7ada: primera plataforma per a virus adenoassociats en ter\u00e0pia g\u00e8nica"},"content":{"rendered":"<p>En un pas significatiu per millorar el camp de la ter\u00e0pia g\u00e8nica, Kymos ha unit forces amb la UNITAT DE PRODUCCI\u00d3 DE VECTORS VIRALS, una col\u00b7laboraci\u00f3 entre la Universitat Aut\u00f2noma de Barcelona i l&#8217;Institut de Recerca Vall d&#8217;Hebron. Junts, estem embarcant-nos en un projecte per estudiar i desenvolupar una plataforma tecnol\u00f2gica d&#8217;\u00faltima generaci\u00f3 per a assaigs de ter\u00e0pia g\u00e8nica, centrada espec\u00edficament en virus adenoassociats (AAV). <\/p>\n<p>Sota l&#8217;identificador de projecte CDTI IDI-20230061, assignat a Kymos el 27 de gener de 2023, aquesta col\u00b7laboraci\u00f3 pret\u00e9n aconseguir dos objectius vitals. En primer lloc, pret\u00e9n desenvolupar la primera plataforma tecnol\u00f2gica de proves per caracteritzar i definir els atributs de qualitat dels f\u00e0rmacs de ter\u00e0pia g\u00e8nica centrats en virus adenoassociats. En segon lloc, el projecte pret\u00e9n introduir al mercat un servei integral de caracteritzaci\u00f3 i control de qualitat, ofert dins d&#8217;un entorn regulat i validat. En assolir aquests objectius, el projecte pret\u00e9n reduir significativament el temps de desenvolupament necessari per als nous f\u00e0rmacs de ter\u00e0pia g\u00e8nica.   <\/p>\n<p>La import\u00e0ncia estrat\u00e8gica d&#8217;aquesta recerca ha rebut el suport de l&#8217;INSTITUT DE SALUT CARLOS III (ISCIII) i del CENTRE PER AL DESENVOLUPAMENT TECNOL\u00d2GIC I INDUSTRIAL (CDTI), que l&#8217;han inclosa en el Projecte Estrat\u00e8gic per a la Recuperaci\u00f3 Econ\u00f2mica i la Transformaci\u00f3 per a la Salut de Vanguard, un component important del pla m\u00e9s ampli de Recuperaci\u00f3, Transformaci\u00f3 i Resili\u00e8ncia, recolzat pels fons NextGenerationEU. Finalment, per donar suport tamb\u00e9 a aquesta recerca, el projecte ha aconseguit finan\u00e7ament mitjan\u00e7ant una subvenci\u00f3 TORRES QUEVEDO per als contractes n\u00fam.  PTQ2021-012177 de l&#8217;1 de novembre de 2022.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>En un pas significatiu per millorar el camp de la  [&#8230;]<\/p>\n","protected":false},"author":7,"featured_media":15308,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[95,97],"tags":[67],"class_list":["post-22715","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-bioanalisi","category-cmc-ca","tag-carles"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>ATMP: Productes medicinals de ter\u00e0pia avan\u00e7ada | Kymos Group<\/title>\n<meta name=\"description\" content=\"Comunicaci\u00f3 de not\u00edcies sobre l&#039;estudi i desenvolupament de la primera plataforma tecnol\u00f2gica d&#039;assaigs per a virus adenoassociats en ter\u00e0pia g\u00e8nica per part de Kymos.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/kymos.com\/ca\/news\/productes-medicinals-de-terapia-avancada-primera-plataforma-per-a-virus-adenoassociats-en-terapia-genica\/\" \/>\n<meta property=\"og:locale\" content=\"ca_ES\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"ATMP: Productes medicinals de ter\u00e0pia avan\u00e7ada | Kymos Group\" \/>\n<meta property=\"og:description\" content=\"Comunicaci\u00f3 de not\u00edcies sobre l&#039;estudi i desenvolupament de la primera plataforma tecnol\u00f2gica d&#039;assaigs per a virus adenoassociats en ter\u00e0pia g\u00e8nica per part de Kymos.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/kymos.com\/ca\/news\/productes-medicinals-de-terapia-avancada-primera-plataforma-per-a-virus-adenoassociats-en-terapia-genica\/\" \/>\n<meta property=\"og:site_name\" content=\"Kymos\" \/>\n<meta property=\"article:published_time\" content=\"2023-06-19T12:34:46+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/kymos.com\/wp-content\/uploads\/2023\/06\/Captura-2.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1397\" \/>\n\t<meta property=\"og:image:height\" content=\"720\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Carles Celma\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@KymosGroup\" \/>\n<meta name=\"twitter:site\" content=\"@KymosGroup\" \/>\n<meta name=\"twitter:label1\" content=\"Escrit per\" \/>\n\t<meta name=\"twitter:data1\" content=\"Carles Celma\" \/>\n\t<meta name=\"twitter:label2\" content=\"Temps estimat de lectura\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minut\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/kymos.com\\\/ca\\\/news\\\/productes-medicinals-de-terapia-avancada-primera-plataforma-per-a-virus-adenoassociats-en-terapia-genica\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/kymos.com\\\/ca\\\/news\\\/productes-medicinals-de-terapia-avancada-primera-plataforma-per-a-virus-adenoassociats-en-terapia-genica\\\/\"},\"author\":{\"name\":\"Carles Celma\",\"@id\":\"https:\\\/\\\/kymos.com\\\/ca\\\/#\\\/schema\\\/person\\\/3d86e112b87df4b5c1304ce33368ef23\"},\"headline\":\"Productes medicinals de ter\u00e0pia avan\u00e7ada: primera plataforma per a virus adenoassociats en ter\u00e0pia g\u00e8nica\",\"datePublished\":\"2023-06-19T12:34:46+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/kymos.com\\\/ca\\\/news\\\/productes-medicinals-de-terapia-avancada-primera-plataforma-per-a-virus-adenoassociats-en-terapia-genica\\\/\"},\"wordCount\":307,\"image\":{\"@id\":\"https:\\\/\\\/kymos.com\\\/ca\\\/news\\\/productes-medicinals-de-terapia-avancada-primera-plataforma-per-a-virus-adenoassociats-en-terapia-genica\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/kymos.com\\\/wp-content\\\/uploads\\\/2023\\\/06\\\/Captura-2.jpg\",\"keywords\":[\"carles\"],\"articleSection\":[\"Bioan\u00e0lisi\",\"CMC\"],\"inLanguage\":\"ca\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/kymos.com\\\/ca\\\/news\\\/productes-medicinals-de-terapia-avancada-primera-plataforma-per-a-virus-adenoassociats-en-terapia-genica\\\/\",\"url\":\"https:\\\/\\\/kymos.com\\\/ca\\\/news\\\/productes-medicinals-de-terapia-avancada-primera-plataforma-per-a-virus-adenoassociats-en-terapia-genica\\\/\",\"name\":\"ATMP: Productes medicinals de ter\u00e0pia avan\u00e7ada | Kymos Group\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/kymos.com\\\/ca\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/kymos.com\\\/ca\\\/news\\\/productes-medicinals-de-terapia-avancada-primera-plataforma-per-a-virus-adenoassociats-en-terapia-genica\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/kymos.com\\\/ca\\\/news\\\/productes-medicinals-de-terapia-avancada-primera-plataforma-per-a-virus-adenoassociats-en-terapia-genica\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/kymos.com\\\/wp-content\\\/uploads\\\/2023\\\/06\\\/Captura-2.jpg\",\"datePublished\":\"2023-06-19T12:34:46+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/kymos.com\\\/ca\\\/#\\\/schema\\\/person\\\/3d86e112b87df4b5c1304ce33368ef23\"},\"description\":\"Comunicaci\u00f3 de not\u00edcies sobre l'estudi i desenvolupament de la primera plataforma tecnol\u00f2gica d'assaigs per a virus adenoassociats en ter\u00e0pia g\u00e8nica per part de Kymos.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/kymos.com\\\/ca\\\/news\\\/productes-medicinals-de-terapia-avancada-primera-plataforma-per-a-virus-adenoassociats-en-terapia-genica\\\/#breadcrumb\"},\"inLanguage\":\"ca\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/kymos.com\\\/ca\\\/news\\\/productes-medicinals-de-terapia-avancada-primera-plataforma-per-a-virus-adenoassociats-en-terapia-genica\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"ca\",\"@id\":\"https:\\\/\\\/kymos.com\\\/ca\\\/news\\\/productes-medicinals-de-terapia-avancada-primera-plataforma-per-a-virus-adenoassociats-en-terapia-genica\\\/#primaryimage\",\"url\":\"https:\\\/\\\/kymos.com\\\/wp-content\\\/uploads\\\/2023\\\/06\\\/Captura-2.jpg\",\"contentUrl\":\"https:\\\/\\\/kymos.com\\\/wp-content\\\/uploads\\\/2023\\\/06\\\/Captura-2.jpg\",\"width\":1397,\"height\":720},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/kymos.com\\\/ca\\\/news\\\/productes-medicinals-de-terapia-avancada-primera-plataforma-per-a-virus-adenoassociats-en-terapia-genica\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/kymos.com\\\/ca\\\/inici\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Productes medicinals de ter\u00e0pia avan\u00e7ada: primera plataforma per a virus adenoassociats en ter\u00e0pia g\u00e8nica\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/kymos.com\\\/ca\\\/#website\",\"url\":\"https:\\\/\\\/kymos.com\\\/ca\\\/\",\"name\":\"Kymos Group\",\"description\":\"Kymos Group\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/kymos.com\\\/ca\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"ca\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/kymos.com\\\/ca\\\/#\\\/schema\\\/person\\\/3d86e112b87df4b5c1304ce33368ef23\",\"name\":\"Carles Celma\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"ca\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/f7ec8bcf3304288056fadfac1c80186a100e5bc223991385f6f2e5e4c8a55099?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/f7ec8bcf3304288056fadfac1c80186a100e5bc223991385f6f2e5e4c8a55099?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/f7ec8bcf3304288056fadfac1c80186a100e5bc223991385f6f2e5e4c8a55099?s=96&d=mm&r=g\",\"caption\":\"Carles Celma\"},\"url\":\"https:\\\/\\\/kymos.com\\\/ca\\\/news\\\/author\\\/dr-carles-celma\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"ATMP: Productes medicinals de ter\u00e0pia avan\u00e7ada | Kymos Group","description":"Comunicaci\u00f3 de not\u00edcies sobre l'estudi i desenvolupament de la primera plataforma tecnol\u00f2gica d'assaigs per a virus adenoassociats en ter\u00e0pia g\u00e8nica per part de Kymos.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/kymos.com\/ca\/news\/productes-medicinals-de-terapia-avancada-primera-plataforma-per-a-virus-adenoassociats-en-terapia-genica\/","og_locale":"ca_ES","og_type":"article","og_title":"ATMP: Productes medicinals de ter\u00e0pia avan\u00e7ada | Kymos Group","og_description":"Comunicaci\u00f3 de not\u00edcies sobre l'estudi i desenvolupament de la primera plataforma tecnol\u00f2gica d'assaigs per a virus adenoassociats en ter\u00e0pia g\u00e8nica per part de Kymos.","og_url":"https:\/\/kymos.com\/ca\/news\/productes-medicinals-de-terapia-avancada-primera-plataforma-per-a-virus-adenoassociats-en-terapia-genica\/","og_site_name":"Kymos","article_published_time":"2023-06-19T12:34:46+00:00","og_image":[{"width":1397,"height":720,"url":"https:\/\/kymos.com\/wp-content\/uploads\/2023\/06\/Captura-2.jpg","type":"image\/jpeg"}],"author":"Carles Celma","twitter_card":"summary_large_image","twitter_creator":"@KymosGroup","twitter_site":"@KymosGroup","twitter_misc":{"Escrit per":"Carles Celma","Temps estimat de lectura":"1 minut"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/kymos.com\/ca\/news\/productes-medicinals-de-terapia-avancada-primera-plataforma-per-a-virus-adenoassociats-en-terapia-genica\/#article","isPartOf":{"@id":"https:\/\/kymos.com\/ca\/news\/productes-medicinals-de-terapia-avancada-primera-plataforma-per-a-virus-adenoassociats-en-terapia-genica\/"},"author":{"name":"Carles Celma","@id":"https:\/\/kymos.com\/ca\/#\/schema\/person\/3d86e112b87df4b5c1304ce33368ef23"},"headline":"Productes medicinals de ter\u00e0pia avan\u00e7ada: primera plataforma per a virus adenoassociats en ter\u00e0pia g\u00e8nica","datePublished":"2023-06-19T12:34:46+00:00","mainEntityOfPage":{"@id":"https:\/\/kymos.com\/ca\/news\/productes-medicinals-de-terapia-avancada-primera-plataforma-per-a-virus-adenoassociats-en-terapia-genica\/"},"wordCount":307,"image":{"@id":"https:\/\/kymos.com\/ca\/news\/productes-medicinals-de-terapia-avancada-primera-plataforma-per-a-virus-adenoassociats-en-terapia-genica\/#primaryimage"},"thumbnailUrl":"https:\/\/kymos.com\/wp-content\/uploads\/2023\/06\/Captura-2.jpg","keywords":["carles"],"articleSection":["Bioan\u00e0lisi","CMC"],"inLanguage":"ca"},{"@type":"WebPage","@id":"https:\/\/kymos.com\/ca\/news\/productes-medicinals-de-terapia-avancada-primera-plataforma-per-a-virus-adenoassociats-en-terapia-genica\/","url":"https:\/\/kymos.com\/ca\/news\/productes-medicinals-de-terapia-avancada-primera-plataforma-per-a-virus-adenoassociats-en-terapia-genica\/","name":"ATMP: Productes medicinals de ter\u00e0pia avan\u00e7ada | Kymos Group","isPartOf":{"@id":"https:\/\/kymos.com\/ca\/#website"},"primaryImageOfPage":{"@id":"https:\/\/kymos.com\/ca\/news\/productes-medicinals-de-terapia-avancada-primera-plataforma-per-a-virus-adenoassociats-en-terapia-genica\/#primaryimage"},"image":{"@id":"https:\/\/kymos.com\/ca\/news\/productes-medicinals-de-terapia-avancada-primera-plataforma-per-a-virus-adenoassociats-en-terapia-genica\/#primaryimage"},"thumbnailUrl":"https:\/\/kymos.com\/wp-content\/uploads\/2023\/06\/Captura-2.jpg","datePublished":"2023-06-19T12:34:46+00:00","author":{"@id":"https:\/\/kymos.com\/ca\/#\/schema\/person\/3d86e112b87df4b5c1304ce33368ef23"},"description":"Comunicaci\u00f3 de not\u00edcies sobre l'estudi i desenvolupament de la primera plataforma tecnol\u00f2gica d'assaigs per a virus adenoassociats en ter\u00e0pia g\u00e8nica per part de Kymos.","breadcrumb":{"@id":"https:\/\/kymos.com\/ca\/news\/productes-medicinals-de-terapia-avancada-primera-plataforma-per-a-virus-adenoassociats-en-terapia-genica\/#breadcrumb"},"inLanguage":"ca","potentialAction":[{"@type":"ReadAction","target":["https:\/\/kymos.com\/ca\/news\/productes-medicinals-de-terapia-avancada-primera-plataforma-per-a-virus-adenoassociats-en-terapia-genica\/"]}]},{"@type":"ImageObject","inLanguage":"ca","@id":"https:\/\/kymos.com\/ca\/news\/productes-medicinals-de-terapia-avancada-primera-plataforma-per-a-virus-adenoassociats-en-terapia-genica\/#primaryimage","url":"https:\/\/kymos.com\/wp-content\/uploads\/2023\/06\/Captura-2.jpg","contentUrl":"https:\/\/kymos.com\/wp-content\/uploads\/2023\/06\/Captura-2.jpg","width":1397,"height":720},{"@type":"BreadcrumbList","@id":"https:\/\/kymos.com\/ca\/news\/productes-medicinals-de-terapia-avancada-primera-plataforma-per-a-virus-adenoassociats-en-terapia-genica\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/kymos.com\/ca\/inici\/"},{"@type":"ListItem","position":2,"name":"Productes medicinals de ter\u00e0pia avan\u00e7ada: primera plataforma per a virus adenoassociats en ter\u00e0pia g\u00e8nica"}]},{"@type":"WebSite","@id":"https:\/\/kymos.com\/ca\/#website","url":"https:\/\/kymos.com\/ca\/","name":"Kymos Group","description":"Kymos Group","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/kymos.com\/ca\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"ca"},{"@type":"Person","@id":"https:\/\/kymos.com\/ca\/#\/schema\/person\/3d86e112b87df4b5c1304ce33368ef23","name":"Carles Celma","image":{"@type":"ImageObject","inLanguage":"ca","@id":"https:\/\/secure.gravatar.com\/avatar\/f7ec8bcf3304288056fadfac1c80186a100e5bc223991385f6f2e5e4c8a55099?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/f7ec8bcf3304288056fadfac1c80186a100e5bc223991385f6f2e5e4c8a55099?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/f7ec8bcf3304288056fadfac1c80186a100e5bc223991385f6f2e5e4c8a55099?s=96&d=mm&r=g","caption":"Carles Celma"},"url":"https:\/\/kymos.com\/ca\/news\/author\/dr-carles-celma\/"}]}},"_links":{"self":[{"href":"https:\/\/kymos.com\/ca\/wp-json\/wp\/v2\/posts\/22715","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/kymos.com\/ca\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/kymos.com\/ca\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/kymos.com\/ca\/wp-json\/wp\/v2\/users\/7"}],"replies":[{"embeddable":true,"href":"https:\/\/kymos.com\/ca\/wp-json\/wp\/v2\/comments?post=22715"}],"version-history":[{"count":0,"href":"https:\/\/kymos.com\/ca\/wp-json\/wp\/v2\/posts\/22715\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/kymos.com\/ca\/wp-json\/wp\/v2\/media\/15308"}],"wp:attachment":[{"href":"https:\/\/kymos.com\/ca\/wp-json\/wp\/v2\/media?parent=22715"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/kymos.com\/ca\/wp-json\/wp\/v2\/categories?post=22715"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/kymos.com\/ca\/wp-json\/wp\/v2\/tags?post=22715"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}